

# miRNA, piRNA and snoRNA expression profile analysis in thyroid cancer subtypes

Mayla Abraham Costa<sup>1</sup>, Natasha Jorge<sup>2</sup>, Fabio Passetti<sup>2</sup>,

*1 IOC/FIOCRUZ - RJ*

*2 FIOCRUZ - IOC*

## Abstract

Thyroid cancer is a public health problem and is considered the most common malignant tumor of the endocrine system. Different treatment strategies have been developed to improve patient's condition, including the identification of molecular markers. Over the years, non-coding RNAs (ncRNAs) have been identified as potential molecular markers capable of predicting therapeutic outcome. Studies show that small ncRNAs (sncRNAs), such as microRNAs (miRNAs), Piwi-interacting RNA (piRNA) and small nucleolar RNAs (snoRNAs) play important roles in cancer and response to treatment. In order to identify the miRNA, piRNA and snoRNAs constitutively and differentially expressed in samples of the different thyroid cancer subtypes, we analyzed small RNA high throughput sequencing data of thyroid carcinoma samples. We obtained normal and tumor samples of carcinoma papillary (PTC) (49 patients), carcinoma papillary, follicular variant, (PCF) (7 patients), and carcinoma papillary, columnar cell variant, (PCC) (3 patients), accounting for 118 paired samples available at the Genome Atlas Database. Forty six differentially expressed sncRNAs were obtained, of which 40 were miRNAs. Among them, 21 were detected as up regulated in tumor samples and 19 were down regulated. A total of 6 snoRNAs have been detected differentially expressed in all comparisons, 2 more expressed in tumor samples and 4 snoRNAs more expressed in control samples from the tissue adjacent to the tumor. We identified 34 constitutively expressed sncRNAs, including the piRNA hsa-piR-009294, in the 3 tumor subtypes. The integration of the differential expression and dispersion analysis revealed 3 miRNAs presenting similar expression pattern in tumor subtypes PCC and PTC when compared to the constitutive expression pattern in control and tumor samples of the PCF subtype. These results show that it was possible to detect sncRNAs differentially and constitutively expressed in samples of the different thyroid cancer subtypes. Our results corroborate those obtained by others and present novel findings, evidencing a viable alternative to search for novel potential molecular markers.

Funding: CAPES, FAPERJ and FIOCRUZ